Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential
暂无分享,去创建一个
[1] P. Cullis,et al. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. , 1989, Magnetic resonance imaging.
[2] P. Turski,et al. Magnetic resonance imaging of rabbit brain after intracarotid injection of large multivesicular liposomes containing paramagnetic metals and DTPA , 1988, Magnetic resonance in medicine.
[3] Steven J Wang,et al. Characteristics of a New MRI Contrast Agent Prepared From Polypropyleneimine Dendrimers, Generation 2 , 2003, Investigative radiology.
[4] K. Hubner,et al. Gd-labeled liposomes containing amphipathic agents for magnetic resonance imaging. , 1990, Investigative radiology.
[5] R Weissleder,et al. A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. , 1993, Radiology.
[6] M. Brechbiel,et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). , 2002, Cancer research.
[7] D M Shames,et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology , 2001, Magnetic resonance in medicine.
[8] P. Anelli,et al. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. , 2002, Academic radiology.
[9] M. Brechbiel,et al. Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.
[10] E. Unger,et al. Liposomes as MR contrast agents: Pros and cons , 1991, Magnetic resonance in medicine.
[11] S. F. Quinn,et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study. , 2005, Radiology.
[12] R. Clarkson. Blood-Pool MRI Contrast Agents: Properties and Characterization , 2002 .
[13] L. Helm,et al. Gadolinium‐based linear polymer with temperature‐independent proton relaxivities: a unique interplay between the water exchange and rotational contributions , 1998 .
[14] M. Brechbiel,et al. Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64). , 2001, Cancer research.
[15] L. Huang,et al. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. , 1991, Magnetic resonance imaging.
[16] W. A. Murphy,et al. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. , 1985, Investigative radiology.
[17] D Revel,et al. Kinetic characterization of CMD‐A2‐Gd‐DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI , 2000, Magnetic resonance in medicine.
[18] M. Schaefer,et al. Paramagnetic dextrans as magnetic resonance blood pool tracers. , 1994, Investigative radiology.
[19] H. Weinmann,et al. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. , 1991, Investigative radiology.
[20] M. Schabel,et al. Pharmacokinetics and Tissue Retention of (Gd-DTPA)-Cystamine Copolymers, a Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agent , 2005, Pharmaceutical Research.
[21] T L Chenevert,et al. Magnetic resonance angiography with gadomer-17. An animal study original investigation. , 1998, Investigative radiology.
[22] E M Haacke,et al. Intravascular contrast agent improves magnetic resonance angiography of carotid arteries in minipigs , 1997, Journal of magnetic resonance imaging : JMRI.
[23] J Lautrou,et al. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. , 2001, Investigative radiology.
[24] J. Bulte,et al. Pharmacokinetics of a high-generation dendrimer-Gd-DOTA. , 2002, Academic radiology.
[25] M. Brechbiel,et al. 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent , 2001, Magnetic resonance in medicine.
[26] R. Müller,et al. Dendrimers in Diagnostics , 2000 .
[27] K. Nicolay,et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. , 2004, Bioconjugate chemistry.
[28] T. Desser,et al. Interstitial MR and CT lymphography with Gd-DTPA-co-α, ω-diaminoPEG(1450) and Gd-DTPA-co-1,6-diaminohexane polymers: Preliminary experience , 1999 .
[29] G. Frija,et al. Capillary leakage of a macromolecular MRI agent, carboxymethyldextran-Gd-DTPA, in the liver: pharmacokinetics and imaging implications. , 1996, Magnetic resonance imaging.
[30] M. Moseley,et al. Magnetic Resonance Imaging Detection of an Experimental Pulmonary Perfusion Deficit Using a Macromolecular Contrast Agent: Polylysine–Gadolinium-DTPA40 , 1992, Investigative radiology.
[31] A de Roos,et al. Equilibrium phase MR angiography of the aortic arch and abdominal vasculature with the blood pool contrast agent CMD‐A2‐Gd‐DOTA in pigs , 1999, Journal of magnetic resonance imaging : JMRI.
[32] A de Roos,et al. Blood pool contrast agents for cardiovascular MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.
[33] Peter Caravan,et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.
[34] R. Dolan,et al. MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.
[35] A. Mohs,et al. Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents , 2006, International journal of nanomedicine.
[36] P S Tofts,et al. Measurement of blood‐brain barrier permeability using dynamic Gd‐DTPA scanning—a comparison of methods , 1992, Magnetic resonance in medicine.
[37] G. Adam,et al. Gd‐DTPA‐cascade‐polymer: Potential blood pool contrast agent for MR imaging , 1994, Journal of magnetic resonance imaging : JMRI.
[38] D. Parker,et al. PEG-g-poly(GdDTPA-co-L-cystine): effect of PEG chain length on in vivo contrast enhancement in MRI. , 2005, Biomacromolecules.
[39] R. Felix,et al. Hemodynamic tolerance of intravascular contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.
[40] Wolfgang Ebert,et al. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[41] K. Scheffler,et al. B22956/1, a new intravascular contrast agent for MRI: first administration to humans--preliminary results. , 2002, Academic radiology.
[42] T K Foo,et al. Contrast-Enhanced Magnetic Resonance Angiography: Technical Considerations for Optimized Clinical Implementation , 2001, Topics in magnetic resonance imaging : TMRI.
[43] M. Moseley,et al. Differentiation of capillary leak and hydrostatic pulmonary edema with a macromolecular MR imaging contrast agent. , 1991, Radiology.
[44] David A. Cheresh,et al. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.
[45] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[46] P. M. Henrichs,et al. High relaxivity linear Gd(DTPA)‐polymer conjugates: The role of hydrophobic interactions , 1997, Magnetic resonance in medicine.
[47] Hisataka Kobayashi,et al. Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. , 2003, Bioconjugate chemistry.
[48] M. Botta,et al. Novel paramagnetic macromolecular complexes derived from the linkage of a macrocyclic Gd(III) complex to polyamino acids through a squaric acid moiety. , 1999, Bioconjugate chemistry.
[49] R. Brasch,et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.
[50] Michael V Knopp,et al. Comparison of dendrimer‐based macromolecular contrast agents for dynamic micro‐magnetic resonance lymphangiography , 2003, Magnetic resonance in medicine.
[51] P. Tofts,et al. Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.
[52] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[53] E. Unger,et al. Detailed toxicity studies of liposomal gadolinium-DTPA. , 1991, Investigative radiology.
[54] E. R. Birnbaum,et al. Lanthanide ions activate alpha-amylase. , 1973, Biochemistry.
[55] J. Lansman. Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit , 1990, The Journal of general physiology.
[56] P. Joseph,et al. Nuclear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[58] J. Hagan,et al. Comparative Chemical Structure and Pharmacokinetics of MRI Contrast Agents , 1988, Investigative radiology.
[59] David R Vera,et al. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. , 2004, Academic radiology.
[60] N. van Bruggen,et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.
[61] Shihua Zhao,et al. Carboxymethyl-dextran-gadolinium-DTPA as a blood-pool contrast agent for magnetic resonance angiography. Experimental study in rabbits. , 1996, Investigative radiology.
[62] M. Wendland,et al. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. , 1998, Academic radiology.
[63] K Togashi,et al. Positive effects of polyethylene glycol conjugation to generation‐4 polyamidoamine dendrimers as macromolecular MR contrast agents , 2001, Magnetic resonance in medicine.
[64] D M Shames,et al. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. , 2000, Academic radiology.
[65] A. Sherry,et al. Stability constants for Gd3+ binding to model DTPA‐conjugates and DTPA‐proteins: Implications for their use as magnetic resonance contrast agents , 1988, Magnetic resonance in medicine.
[66] C. Yuan,et al. Time‐of‐flight MR angiography with Gd‐DTPA hexamethylene diamine co‐polymer blood pool contrast agent: Comparison of enhanced MRA and conventional angiography for arterial stenosis induced in rabbits , 2000, Journal of magnetic resonance imaging : JMRI.
[67] R. Muller,et al. Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. , 1998, Investigative radiology.
[68] P. Anelli,et al. Gadocoletic Acid Trisodium Salt (B22956/1): A New Blood Pool Magnetic Resonance Contrast Agent With Application in Coronary Angiography , 2006, Investigative radiology.
[69] G. Frija,et al. Measurement of liver blood volume using a macromolecular MRI contrast agent at equilibrium. , 1997, Magnetic resonance imaging.
[70] E. Rofstad,et al. Transvascular and interstitial transport of a 19 kDa linear molecule in human melanoma xenografts measured by contrast‐enhanced magnetic resonance imaging , 2001, Journal of magnetic resonance imaging : JMRI.
[71] Z. Lu,et al. Water soluble polymers in tumor targeted delivery. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[72] M. Brechbiel,et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.
[73] Michel Schneider,et al. Gadolinium-containing mixed micelle formulations: a new class of blood pool MRI/MRA contrast agents. , 2002, Academic radiology.
[74] C. Higgins,et al. Myocardial infarction: assessment with an intravascular MR contrast medium. Work in progress. , 1991, Radiology.
[75] W. Ebert,et al. The Demonstration of Human Tumors on Nude Mice Using Gadolinium‐Labelled Monoclonal Antibodies for Magnetic Resonance Imaging , 1993, Investigative radiology.
[76] R. Dolan,et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. , 1996, Academic radiology.
[77] T. Helbich,et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS‐325) with correlations to histopathology , 2001, Journal of magnetic resonance imaging : JMRI.
[78] O. Nalcioglu,et al. Measurement of tumor vascular volume and mean microvascular random flow velocity magnitude by dynamic GD‐DTPA‐Albumin enhanced and diffusion‐weighted MRI , 1998, Magnetic resonance in medicine.
[79] Akira Hiraga,et al. Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core , 2001, Magnetic resonance in medicine.
[80] M. Brechbiel,et al. Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. , 1995, Magnetic resonance imaging.
[81] F. Vögtle,et al. Dendrimers: From Design to Application-A Progress Report. , 1999, Angewandte Chemie.
[82] M. Ogan,et al. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.
[83] Yi Wang,et al. Contrast-enhanced magnetic resonance angiography with biodegradable (Gd-DTPA)-cystamine copolymers: comparison with MS-325 in a swine model. , 2006, Molecular pharmaceutics.
[84] V. Fuster,et al. MRI to detect atherosclerosis with gadolinium‐containing immunomicelles targeting the macrophage scavenger receptor , 2006, Magnetic resonance in medicine.
[85] Young Hwan Kim,et al. Occlusive and reperfused myocardial infarction: detection by using MR imaging with gadolinium polylysine enhancement. , 1993, Radiology.
[86] D M Shames,et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.
[87] É. Tóth,et al. The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. , 2002, Chemistry.
[88] A. D. Watson,et al. Preparation and characterization of paramagnetic polychelates and their protein conjugates. , 1990, Bioconjugate chemistry.
[89] R. Brasch,et al. Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas. , 1994, Investigative radiology.
[90] T. Trouard,et al. Gadolinium-containing copolymeric chelates—a new potential MR contrast agent , 1999, Magnetic Resonance Materials in Physics, Biology and Medicine.
[91] J. Davies,et al. Non-Gadolinium-Based MRI Contrast Agents , 2002 .
[92] E. Unger,et al. Biodistribution and clearance of liposomal gadolinium-DTPA. , 1990, Investigative radiology.
[93] Sheng-Kwei Song,et al. High‐resolution MRI characterization of human thrombus using a novel fibrin‐targeted paramagnetic nanoparticle contrast agent , 2000, Magnetic resonance in medicine.
[94] S. Reingold,et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.
[95] R J van der Geest,et al. Blood pool contrast agent CMD‐A2‐Gd‐DOTA‐enhanced MR imaging of infarcted myocardium in pigs , 1999, Journal of magnetic resonance imaging : JMRI.
[96] Hisataka Kobayashi,et al. Nano-sized MRI contrast agents with dendrimer cores. , 2005, Advanced drug delivery reviews.
[97] P C Lauterbur,et al. Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.
[98] Xiaoping Hu,et al. Long‐circulating liposomal contrast agents for magnetic resonance imaging , 2006, Magnetic resonance in medicine.
[99] E. Uzgiris,et al. Tumor imaging with a macromolecular paramagnetic contrast agent: gadopentetate dimeglumine-polylysine. , 1995, Academic radiology.
[100] Joop A. Peters,et al. Inulin as a carrier for contrast agents in magnetic resonance imaging. , 2001, Chemistry.
[101] Isabelle Raynal,et al. Physical, chemical, and biological evaluations of P760: A new gadolinium complex characterized by a low rate of interstitial diffusion , 2000, Journal of magnetic resonance imaging : JMRI.
[102] U Schmiedl,et al. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. , 1987, Radiology.
[103] É. Tóth,et al. From monomers to micelles: investigation of the parameters influencing proton relaxivity , 2002, JBIC Journal of Biological Inorganic Chemistry.
[104] T. Desser,et al. Dynamics of tumor imaging with Gd‐DTPA—polyethylene glycol polymers: Dependence on molecular weight , 1994, Journal of magnetic resonance imaging : JMRI.
[105] R. Lauffer,et al. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .
[106] É. Tóth,et al. Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. , 2005, Chemistry.
[107] R. Brasch,et al. AUR Memorial Award 1991. Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging. Induction and characterization of antibodies in animals. , 1991, Investigative radiology.
[108] D. Bakan,et al. Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. , 1987, Magnetic resonance imaging.
[109] D C Peters,et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.
[110] G. D’Errico,et al. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. , 2004, Journal of the American Chemical Society.
[111] P. Cullis,et al. Liposomal Gd-DTPA: preparation and characterization of relaxivity. , 1989, Radiology.
[112] D. Parker,et al. Contrast‐enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor‐bearing mice , 2005, Magnetic resonance in medicine.
[113] Michal Neeman,et al. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. , 2005, Cancer research.
[114] Hisataka Kobayashi,et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. , 2004, Journal of the National Cancer Institute.
[115] B. Biagi,et al. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. , 1990, The American journal of physiology.
[116] R. Brasch,et al. Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.
[117] M. Brechbiel,et al. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.
[118] G. Choppin,et al. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. , 2001, Inorganic chemistry.
[119] D. Parker,et al. Pharmacokinetics, Biodistribution and Contrast Enhanced MR Blood Pool Imaging of Gd-DTPA Cystine Copolymers and Gd-DTPA Cystine Diethyl Ester Copolymers in a Rat Model , 2006, Pharmaceutical Research.
[120] M. Brechbiel,et al. Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine , 2001, Magnetic resonance in medicine.
[121] D. Parker,et al. PEG-g-poly(GdDTPA-co-L-cystine): a biodegradable macromolecular blood pool contrast agent for MR imaging. , 2004, Bioconjugate chemistry.
[122] Zahi A Fayad,et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI , 2007, Proceedings of the National Academy of Sciences.
[123] K. Hubner,et al. Gadolinium‐labeled liposomes containing paramagnetic amphipathic agents: Targeted MRI contrast agents for the liver , 1988, Magnetic resonance in medicine.
[124] T. Helbich,et al. A new polysaccharide macromolecular contrast agent for MR imaging: Biodistribution and imaging characteristics , 2000, Journal of magnetic resonance imaging : JMRI.
[125] D. Parker,et al. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI , 2004, Magnetic resonance in medicine.
[126] S A Wickline,et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. , 2000, Magnetic resonance in medicine.
[127] V M Runge,et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. , 1985, Magnetic resonance imaging.
[128] H. Paajanen,et al. Proton relaxation enhancement of albumin, immunoglobulin g, and fibrinogen labeled with gd‐dtpa , 1990, Magnetic resonance in medicine.
[129] W. Gibby,et al. Cross-linked DTPA polysaccharides for magnetic resonance imaging. Synthesis and relaxation properties. , 1989, Investigative radiology.
[130] P. Turski,et al. Glioblastoma multiforme: MR imaging at 1.5 and 9.4 T after injection of polylysine-DTPA-Gd in rats. , 1990, AJNR. American journal of neuroradiology.
[131] H. Bosmans,et al. MR angiography with gadopentetate dimeglumine-polylysine: evaluation in rabbits. , 1990, AJR. American journal of roentgenology.
[132] Klaas Nicolay,et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[133] M. Hynes,et al. Gadolinium(III) di- and tetrachelates designed for in vivo noncovalent complexation with plasma proteins: a novel molecular design for blood pool MRI contrast enhancing agents. , 1995, Bioconjugate chemistry.
[134] Hisataka Kobayashi,et al. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. , 2003, Bioconjugate chemistry.
[135] Joop A. Peters,et al. A gadolinium(III) complex of a carboxylic-phosphorus acid derivative of diethylenetriamine covalently bound to inulin, a potential macromolecular MRI contrast agent. , 2004, Bioconjugate chemistry.
[136] E. Unger,et al. Paramagnetic liposomes as magnetic resonance contrast agents. , 1990, Investigative radiology.